Page 34 - Cll News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Investigators say attempts to overcome mutational resistance to Bruton’s tyrosine kinase (BTK) inhibitors have had mixed results among patients who have chronic lymphocytic leukemia (CLL).

Matthew S. Davids, MD, MMSc, discusses key efficacy results from 2 follow-up analyses of the phase 1/2 BRUIN trial evaluating pirtobrutinib.

A CAR NK therapy made from cord blood showed promising responses in patients with relapsed or refractory B-cell malignancies.

A new report compared the blood immune repertoires of patients with chronic lymphocytic leukemia (CLL) who received chemoimmunotherapy and those who received ibrutinib.